drugset / Trial / NCT07297667
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Phase 1
Recruiting
30 enrolled
Canadian Cancer Trials Group
BioCan Rx · collabCanadian Institutes of Health Research (CIHR) · collabUniversity of Calgary · collab
NaSingle-groupOpen-labelTreatment
Summary
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
Timeline
- Start
- 2026-06-30
- Primary completion
- 2028-12-01
- Completion
- 2033-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GCAR1 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |